Reirradiation for locoregionally recurrent non-small cell lung cancer

about

Reirradiation for locoregionally recurrent non-small cell lung cancer

Item

http://www.wikidata.org/entity/Q58804832

description

scientific article published on 01 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Reirradiation for locoregionally recurrent non-small cell lung cancer

@en

Reirradiation for locoregionally recurrent non-small cell lung cancer

@nl

type

Item

label

Reirradiation for locoregionally recurrent non-small cell lung cancer

@en

Reirradiation for locoregionally recurrent non-small cell lung cancer

@nl

prefLabel

Reirradiation for locoregionally recurrent non-small cell lung cancer

@en

Reirradiation for locoregionally recurrent non-small cell lung cancer

@nl

P1476

Reirradiation for locoregionally recurrent non-small cell lung cancer

@en

P2093

Jill Remick

http://www.w3.org/2001/XMLSchema#string

Melissa A L Vyfhuis

http://www.w3.org/2001/XMLSchema#string

Pranshu Mohindra

http://www.w3.org/2001/XMLSchema#string

Shahed Badiyan

http://www.w3.org/2001/XMLSchema#string

Sina Mossahebi

http://www.w3.org/2001/XMLSchema#string

P2860

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Current clinical trials testing the combination of immunotherapy with radiotherapy.

Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.

Proton therapy in clinical practice

Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy.

Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lun

Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis.

P304

S2522-S2536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2017.12.50

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

Suppl 21

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stephanie R Rice

Charles B Simone

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30206496

http://www.w3.org/2001/XMLSchema#string

P932

6123190

http://www.w3.org/2001/XMLSchema#string